SCHEMBL2020584

SCHEMBL2020584

CC(=O)Nc1cccc(Nc2ncnc3[nH]cc(C(=O)c4cccc5ccccc45)c23)c1

nearest known ligand 0.55

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 3/20 0.55
BTK Q06187 11/20 0.48
KDM4E B2RXH2 1/20 0.45
MEN1 O00255 1/20 0.45
MAPT P10636 1/20 0.45
MAPK1 P28482 1/20 0.45
KMT2A Q03164 1/20 0.45
PTK2 Q05397 1/20 0.45
EGFR P00533 2/20 0.44
JAK3 P52333 1/20 0.44
MELK Q14680 1/20 0.44
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2022444 0.88 BTK (0.51) BTKEGFR
SCHEMBL2021223 0.88 BTK (0.60) ABCG2BTK
SCHEMBL2021419 0.86 EGFR (0.54) ABCG2EGFR
SCHEMBL2022472 0.86 EGFR (0.48) ABCG2BTKMAPK1EGFRJAK3
SCHEMBL2023296 0.86 BRAF (0.46) BTKMEN1MAPTKMT2A
SCHEMBL2019802 0.86 ABCG2 (0.54) ABCG2BTKEGFR
SCHEMBL2021310 0.86 BRAF (0.45) BTK
SCHEMBL2020574 0.85 BTK (0.48) BTKEGFR
SCHEMBL15381969 0.82 BTK (0.50) ABCG2BTKEGFR
SCHEMBL2023282 0.82 GCGR (0.47) BTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8580803-B2 Substituted pyrrolo-aminopyrimidine compounds ARQULE, INC. (US) 2013-11-12 US disclosed
US-8580803-B2 Substituted pyrrolo-aminopyrimidine compounds ARQULE, INC. (US) 2013-11-12 US disclosed
US-8580803-B2 Substituted pyrrolo-aminopyrimidine compounds ARQULE, INC. (US) 2013-11-12 US disclosed
CN-102892768-A Substituted pyrrolo-aminopyrimidine compounds ARQULE INC 2013-01-23 CN disclosed
EP-2519525-A2 SUBSTITUTED PYRROLO-AMINOPYRIMIDINE COMPOUNDS ArQule, Inc. (US) 2012-11-07 EP disclosed
WO-2011082273-A2 SUBSTITUTED PYRROLO-AMINOPYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2011-07-07 WO disclosed
WO-2011082273-A2 SUBSTITUTED PYRROLO-AMINOPYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2011-07-07 WO disclosed
US-20110160203-A1 Substituted Pyrrolo-Aminopyrimidine Compounds ARQULE, INC. (US) 2011-06-30 US disclosed
US-20110160203-A1 Substituted Pyrrolo-Aminopyrimidine Compounds ARQULE, INC. (US) 2011-06-30 US disclosed
US-20110160203-A1 Substituted Pyrrolo-Aminopyrimidine Compounds ARQULE, INC. (US) 2011-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160203-A1 Substituted Pyrrolo-Aminopyrimidine Compounds DPYD, TYMP, DHFR ABCG2 1489/4885BTK 1600/4885KDM4E 864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.